Method for the treatment of staphylococcal disease
AssigneeAMBI Inc.
InventorsMichael W. Climo, Gordon L. Archer, Beth P. Goldstein
Life of this patent
Estimating the term…
Abstract
Lysostaphin is an effective antibiotic in the treatment of staphylococcal infection. Large doses of lysostaphin or lysostaphin analogues are effective in short course, or even one dose administrations, in treating and eradicating staphylococcal infections, including those resistant to conventional antibiotics.
Claims17
A method of treating staphylococcal infection in a patient, comprising:
- administering to said patient a single dose of lysostaphin analogue in a dosage of at least 50 mg lysostaphin/kg body weight (mg/kg), wherein said administration is not continued, and said infection is reduced, and
- wherein said infection is one selected from the group consisting of endocarditis, bacteremia, kidney infection, lung infection, skin infection, bone infection, burn infection, wound infection, infection of prosthetic devices and a combination thereof.
A method of treating staphylococcal infection in a patient, comprising:
- administering to said patient an effective amount of lysostaphin analogue in a dosage of at least 50 mg/kg/day, wherein said administration is continued for a period of 1-5 days, and said infection is reduced, and
- wherein said infection is one selected from the group consisting of endocarditis, bacteremia, kidney infection, lung infection, skin infection, bone infection, burn infection, wound infection, infection of prosthetic devices and a combination thereof.
A method of treating staphylococcal infection in a patient, comprising:
- administering to said patient an amount of lysostaphin analogue in a dosage level of at least 50 mg/kg on a first day of treatment, and repeating said administration once or twice, wherein each said repetition is separated by at least one day on which lysostaphin is not administered, and said infection is reduced, and
- wherein said infection is one selected from the group consisting of endocarditis, bacteremia, kidney infection, lung infection, skin infection, bone infection, burn infection, wound infection, infection of prosthetic devices and a combination thereof.
A composition of matter, comprising a single dosage formulation of lysostaphin effective in treating staphylococcal infection in a patient wherein said single dosage composition comprises at least 2,200 mg lysostaphin analogue, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.